Clinical trial
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV…
NCT00051038 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00051038 |
|---|---|
| Title | Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients |
| Official title | A Phase II Study of the Safety and Efficacy of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients Who Have Hepatitis B Viremia While Being Treated With Lamivudine |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | Entecavir |
| Start date | Sep 1, 2002 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jan 3, 2003 |
| Last update posted | Apr 14, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: